Autolus Therapeutics (AUTL) Interest Coverage Ratio (2018 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Interest Coverage Ratio of 3.17 for Q4 2025, down 228.98% year-on-year from 2.46 in Q4 2024, and down 425.97% on a QoQ basis from 0.6 in Q3 2025.
Autolus Therapeutics (AUTL) Interest Coverage Ratio (2018 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Interest Coverage Ratio for 8 consecutive years, with 3.17 the latest figure, recorded in Q4 2025.
- Quarterly Interest Coverage Ratio fell 228.98% year-over-year to 3.17 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 21.04 (up 19.02% YoY) and the FY2025 annual result came in at 1.09, up 29.07% from the prior year.
- Interest Coverage Ratio fell to 3.17 in Q4 2025 per AUTL's latest filing, from 0.6 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for AUTL reached as high as 2.46 in Q4 2024 and fell as low as 38.56 in Q1 2021.
- A 5-year average of 9.36 and a median of 6.07 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio surged 239.15% — and 2025, when it slumped 228.98%.
- Year by year, Interest Coverage Ratio stood at 20.9 in 2021, then surged by 83.88% to 3.37 in 2022, then surged by 47.53% to 1.77 in 2023, then soared by 239.15% to 2.46 in 2024, then sank by 228.98% to 3.17 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 3.17, 0.6, and 0.51 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -3.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.17 |
| Sep 30, 2025 | -0.60 |
| Jun 30, 2025 | -0.51 |
| Mar 31, 2025 | -0.59 |
| Dec 31, 2024 | 2.46 |
| Sep 30, 2024 | -6.35 |
| Jun 30, 2024 | -5.79 |
| Mar 31, 2024 | -2.01 |
| Dec 31, 2023 | -1.77 |
| Sep 30, 2023 | -8.56 |
| Jun 30, 2023 | -8.84 |
| Mar 31, 2023 | -7.98 |
| Dec 31, 2022 | -3.37 |
| Sep 30, 2022 | -20.19 |
| Jun 30, 2022 | -21.58 |
| Mar 31, 2022 | -20.22 |
| Dec 31, 2021 | -20.90 |
| Mar 31, 2021 | -38.56 |
| Dec 31, 2020 | 473.30 |
| Sep 30, 2020 | -427.08 |